On Tuesday, Shares of Nokia Corporation (ADR) (NYSE:NOK), lost -0.68% to $6.61.
Nokia, declared OZO, the first commercially accessible virtual reality (VR) camera designed and built for professional content creators and the first in a planned portfolio of digital media solutions from Nokia Technologies, the company’s advanced technology and licensing business.
“We’re thrilled to introduce OZO to the content creation world, and to define a completely new category of virtual reality capture and playback solutions,” said Ramzi Haidamus, president of Nokia Technologies. “OZO aims to advance the next wave of innovation in VR by putting powerful tools in the hands of professionals who will create amazing experiences for people around the world. We expect that virtual reality experiences will soon radically enhance the way people communicate and connect to stories, entertainment, world events and each other. With OZO, we plan to be at the heart of this new world.”
Nokia Corporation, together with its auxiliaries, provides network infrastructure and related services in Finland, the United States, Japan, China, India, the Russian Federation, Germany, Taiwan, Indonesia, Italy, and internationally.
Shares of Textron Inc. (NYSE:TXT), inclined 5.77% to $42.87, during its last trading session.
Textron Inc., stated second quarter 2015 income from ongoing operations of $0.60 per share, up 17.6 percent from $0.51 per share in the second quarter of 2014.
Revenues in the quarter were $3.2 billion, down 7.4 percent contrast to $3.5 billion in the second quarter of 2014. Textron segment profit in the quarter was $306 million, up $2 million from the second quarter of 2014. Second quarter manufacturing cash flow before pension contributions was $106 million contrast to $271 million during last year’s second quarter.
Textron Inc. operates in the aircraft, defense, industrial, and finance businesses worldwide. It operates through five segments: Textron Aviation, Bell, Textron Systems, Industrial, and Finance.
Finally, Delcath Systems, Inc. (NASDAQ:DCTH), ended its last trade with 0.95% gain, and closed at $0.550.
Delcath Systems, declared that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma. The OOPD is tasked with evaluating the scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products.
Orphan drug designation provides certain exclusivity benefits, tax credits for certain research and a waiver of the New Drug Application user fee. Cholangiocarcinoma is recognized by the FDA as an orphan disease, usually defined as a condition that affects fewer than 200,000 people nationwide.
Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
